BACKGROUND AND PURPOSE: Recanalization is observed in 20-40% of endovascularly treated intracranial aneurysms. To further reduce the recanalization and expand endovascular treatment, we evaluated the safety and efficacy of closed-cell SACE. MATERIALS AND METHODS: Between 2007 and 2010, 147 consecutive patients (110 women; mean age, 54 years) presenting at 2 centers with 161 wide-neck ruptured and unruptured aneurysms were treated by using SACE. Inclusion criteria were wide-neck aneurysms (>4 mm or a dome/neck ratio ≤ 2). Clinical outcomes were assessed by the mRS score at baseline, discharge, and follow-up. Aneurysm occlusion was assessed on angiograms by using the RS immediately after SACE and at follow-up. RESULTS: Eighteen aneurysms (11%) were treated following rupture. Procedure-related mortality and permanent neurologic deficits occurred in 2 (1.4%) and 5 patients (3.4%), respectively. In total, 7 patients (4.8%) died, including 2 with reruptures. Of the 140 surviving patients, 113 (80.7%) patients with 120 aneurysms were available for follow-up neurologic examination at a mean of 11.8 months. An increase in mRS score from admission to follow-up by 1, 2, or 3 points was seen in 7 (6.9%), 1 (1%), and 2 (2%) patients, respectively. Follow-up angiography was performed in 120 aneurysms at a mean of 11.9 months. Recanalization occurred in 12 aneurysms (10%), requiring retreatment in 7 (5.8%). Moderate in-stent stenosis was seen in 1 (0.8%), which remained asymptomatic. CONCLUSIONS: This series adds to the evidence demonstrating the safety and effectiveness of SACE in the treatment of intracranial aneurysms. However, SACE of ruptured aneurysms and premature termination of antiplatelet treatment are associated with increased morbidity and mortality.
BACKGROUND AND PURPOSE: Recanalization is observed in 20-40% of endovascularly treated intracranial aneurysms. To further reduce the recanalization and expand endovascular treatment, we evaluated the safety and efficacy of closed-cell SACE. MATERIALS AND METHODS: Between 2007 and 2010, 147 consecutive patients (110 women; mean age, 54 years) presenting at 2 centers with 161 wide-neck ruptured and unruptured aneurysms were treated by using SACE. Inclusion criteria were wide-neck aneurysms (>4 mm or a dome/neck ratio ≤ 2). Clinical outcomes were assessed by the mRS score at baseline, discharge, and follow-up. Aneurysm occlusion was assessed on angiograms by using the RS immediately after SACE and at follow-up. RESULTS: Eighteen aneurysms (11%) were treated following rupture. Procedure-related mortality and permanent neurologic deficits occurred in 2 (1.4%) and 5 patients (3.4%), respectively. In total, 7 patients (4.8%) died, including 2 with reruptures. Of the 140 surviving patients, 113 (80.7%) patients with 120 aneurysms were available for follow-up neurologic examination at a mean of 11.8 months. An increase in mRS score from admission to follow-up by 1, 2, or 3 points was seen in 7 (6.9%), 1 (1%), and 2 (2%) patients, respectively. Follow-up angiography was performed in 120 aneurysms at a mean of 11.9 months. Recanalization occurred in 12 aneurysms (10%), requiring retreatment in 7 (5.8%). Moderate in-stent stenosis was seen in 1 (0.8%), which remained asymptomatic. CONCLUSIONS: This series adds to the evidence demonstrating the safety and effectiveness of SACE in the treatment of intracranial aneurysms. However, SACE of ruptured aneurysms and premature termination of antiplatelet treatment are associated with increased morbidity and mortality.
Authors: Andrew Molyneux; Richard Kerr; Irene Stratton; Peter Sandercock; Mike Clarke; Julia Shrimpton; Rury Holman Journal: Lancet Date: 2002-10-26 Impact factor: 79.321
Authors: David O Wiebers; J P Whisnant; J Huston; I Meissner; R D Brown; D G Piepgras; G S Forbes; K Thielen; D Nichols; W M O'Fallon; J Peacock; L Jaeger; N F Kassell; G L Kongable-Beckman; J C Torner Journal: Lancet Date: 2003-07-12 Impact factor: 79.321
Authors: Menno Sluzewski; Willem Jan van Rooij; Marian J Slob; Javier Oliván Bescós; Cornelis H Slump; Douwe Wijnalda Journal: Radiology Date: 2004-04-29 Impact factor: 11.105
Authors: Alessandra Biondi; Vallabh Janardhan; Jeffrey M Katz; Kimberly Salvaggio; Howard A Riina; Y Pierre Gobin Journal: Neurosurgery Date: 2007-09 Impact factor: 4.654
Authors: Andrew J Molyneux; Richard S C Kerr; Ly-Mee Yu; Mike Clarke; Mary Sneade; Julia A Yarnold; Peter Sandercock Journal: Lancet Date: 2005 Sep 3-9 Impact factor: 79.321
Authors: A K Wakhloo; P Lylyk; J de Vries; C Taschner; J Lundquist; A Biondi; M Hartmann; I Szikora; L Pierot; N Sakai; H Imamura; N Sourour; I Rennie; M Skalej; O Beuing; A Bonafé; F Mery; F Turjman; P Brouwer; E Boccardi; L Valvassori; S Derakhshani; M W Litzenberg; M J Gounis Journal: AJNR Am J Neuroradiol Date: 2014-08-14 Impact factor: 3.825
Authors: R S Bechan; M E Sprengers; C B Majoie; J P Peluso; M Sluzewski; W J van Rooij Journal: AJNR Am J Neuroradiol Date: 2015-09-24 Impact factor: 3.825
Authors: I M J van der Bom; S Y Hou; A S Puri; G Spilberg; D Ruijters; P van de Haar; B Carelsen; S Vedantham; M J Gounis; A K Wakhloo Journal: AJNR Am J Neuroradiol Date: 2013-05-30 Impact factor: 3.825
Authors: Robert M King; Miklos Marosfoi; Jildaz Caroff; Giovanni J Ughi; Dale M Groth; Matthew J Gounis; Ajit S Puri Journal: J Neurointerv Surg Date: 2019-04-29 Impact factor: 5.836